Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment
This risk prediction model among women with early-stage BC was able to prospectively identify those at risk of HF/CM over a 10-year period based on the selected BC treatment and clinical variables available at BC diagnosis. The model can be used to inform risk-guided cardiac management for these women.
Authors
- Rowan T. Chlebowski (ORCID: https://orcid.org/0000-0002-4212-6184)
- Nawar Shara (ORCID: https://orcid.org/0000-0002-9005-252X)
- Jiling Chou (ORCID: https://orcid.org/0000-0002-0552-0246)
- Ana Barac (ORCID: https://orcid.org/0000-0002-9935-8904)
- Arnold L. Potosky (ORCID: https://orcid.org/0000-0001-8087-6667)
- Jiaxiao Shi (ORCID: https://orcid.org/0000-0001-8397-3729)
- Reina Haque (ORCID: https://orcid.org/0000-0001-8563-3330)
- Lie Hong Chen (ORCID: https://orcid.org/0000-0003-0989-7144)
- Amrita Mukherjee (ORCID: https://orcid.org/0000-0003-1713-2926)
Institutions
- Kaiser Permanente (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- MedStar Health (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1001/jamaoncol.2025.4178
- Citations
- 4
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 5.55